Live
FierceBiotechLabcorp launches rapid fentanyl test with 48-hour detection windowFierceBiotechWas Big Pharma’s ‘unusually aggressive’ M&A spree to blame for March IPO drought?FierceBiotechSpain sets up Boston-focused VC fund with goal of raising $200M for biotechsFierceBiotechNovartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepenEndpoints NewsIn vivo CAR-T race for autoimmune grows as two RNA startups enter the clinicLonza NewsLonza Singapore Lab: Media Development for Bioprocessing Scale-Up | 2026 - News and Statistics - IndexBoxEndpoints NewsBiogen filing reveals Apellis deal details; Telix raises $600MAgilentAgilent (A) Showcases Innovations at AACR 2026 Annual Meeting - GuruFocusEndpoints NewsFormer FDA cancer chief Pazdur warns of the political 'breach' of review teamsEndpoints NewsTampa General's AI journeyEndpoints NewsRevolution Medicines prices $2B raise as XBI reaches heights not seen since pandemicBioPharma DiveObsidian, Galera to advance cell therapy following reverse merger
Lonza News Apr 7, 2026

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development - Manufacturing Chemist

Swiss Rockets collaborates with Lonza to advance Torqur’s oncology drug candidate bimiralisib into late-stage clinical development - Manufacturing Chemist

Original
Body unavailable. Use the original source.

Directory

1122 All